Q: Could you please comment on the latest results which seemed to point to a better future. thanks
Robert
Robert
5i Research Answer:
MBX reported record levels of revenue and net income in Q1. Q1 revenue was $8.4M, a 236% increase from last year's revenues of $2.5M. Q1 revenues were also greatly influenced by the recognition of $4.1M in Kinlytic licensing milestone payments the company said. The company did demonstrate strong growth in sales of each of MBX's test ingredients (Antigens) and its test quality assessment products (QAPs), which were collectively up by 80% year-over-year. Net income was $2.45M, compared with a loss of $(1.3M), last year. This was definitely a good quarter for the company and increasing demand for its products is showing. MBX is a microcap stock at $56M market cap so things will remain volatile going forward.